Al­most all dos­es of Moun­jaro, Zep­bound in short sup­ply through Q2

The FDA up­dat­ed its drug short­ages list this week, not­ing that most of its in­jec­tions of di­a­betes drug Moun­jaro and weight loss drug Zep­bound will be in short sup­ply through the sec­ond quar­ter.

All but one dose of each drug — 2.5 mg of Moun­jaro and 2.5 mg of Zep­bound — are list­ed as ex­pe­ri­enc­ing “lim­it­ed avail­abil­i­ty,” ac­cord­ing to the FDA.

Zep­bound was ap­proved for weight loss in No­vem­ber and al­ready pulled in $175.8 mil­lion as of Feb­ru­ary. The com­pa­ny al­so an­nounced Wednes­day that it would file for a la­bel ex­pan­sion for the drug in sleep ap­nea this year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.